Cambiar Investors LLC Decreases Stake in Medtronic PLC $MDT

Cambiar Investors LLC lowered its position in shares of Medtronic PLC (NYSE:MDT) by 1.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 641,942 shares of the medical technology company’s stock after selling 7,128 shares during the period. Medtronic comprises about 2.4% of Cambiar Investors LLC’s investment portfolio, making the stock its 11th biggest holding. Cambiar Investors LLC owned approximately 0.05% of Medtronic worth $55,958,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in MDT. 1248 Management LLC purchased a new stake in Medtronic during the 1st quarter valued at $26,000. Columbia River Financial Group LLC purchased a new stake in Medtronic during the 1st quarter valued at $28,000. Twin Tree Management LP purchased a new stake in Medtronic during the 1st quarter valued at $29,000. Activest Wealth Management boosted its position in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after buying an additional 322 shares during the period. Finally, Hughes Financial Services LLC purchased a new stake in Medtronic during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.2%

Shares of Medtronic stock opened at $90.82 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The company has a 50-day moving average of $94.35 and a 200 day moving average of $89.72. The firm has a market cap of $116.49 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 2.42 and a beta of 0.78. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Analyst Upgrades and Downgrades

MDT has been the subject of several analyst reports. Morgan Stanley reissued an “overweight” rating and set a $107.00 price target (up previously from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a report on Sunday. UBS Group upped their price objective on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Daiwa Capital Markets upped their price objective on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Finally, Stifel Nicolaus upped their price objective on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $102.82.

Insider Activity

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.26% of the stock is owned by company insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.